Skip to main content
OpenTrials
Completed

NCT Number: NCT06004375

THE EFFECT OF ARGININE AND GLUTAMINE ON COVID-19 PATIENTS OUTCOME: A RANDOMIZED CLINICAL TRIAL

The goal of this clinical trial is to determine effect of arginine and glutamine on outcome of COVID-19 patients. The main questions it aims to answer are:

-to test the effect of oral nutritional supplements containing arginine and glutamine on covid-19 patients outcome Dr. M. Djamil General Hospital Padang

Participants will given ONS containing arginine and glutamine. Researchers will compare intervention group with control group to see if ONS affected outcome of COVID-19 patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Dr. M. Djamil General Hospital

Padang, West Sumatera, 25176, Indonesia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients confirmed positive for COVID-19
  • Age over 17 years
  • The patient can take food orally

Exclusion criteria

  • Patients with restricted fluid intake
  • Patients who cannot take food orally
  • suffering from diabetes mellitus and kidney failure

Treatment and study plan

Neomune

Dietary Supplement

Neomune containing 4.8 g arginine and 2 g glutamine

Primary outcomes

  1. length of stay

    Time frame: 3 months

    length of stay of patients in hospital

  2. Outcome

    Time frame: 3 months

    Outcome Measures of patients (discharge or dead)

  3. ICU Admission

    Time frame: 3 months

    A patient is likely to be admitted to ICU during intervention period

Secondary outcomes

  1. Il-6 and CRP Levels

    Time frame: 3 months

    Il-6 and CRP Levels during hospitalization

Sponsors and collaborators

Lead sponsor

Universitas Sriwijaya

Other

Collaborators

  • M. Djamil General Hospital

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Aug 22, 2023
Registry last updated
Aug 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.